Text Size
15 studies found for:    PARP AND ovarian cancer | Open Studies | Exclude Unknown

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
Conditions: Breast Cancer;   Ovarian Cancer
Interventions: Drug: AZ2281;   Drug: Carboplatin
2 Recruiting An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Conditions: Malignant Solid Tumour;   Ovarian Cancer;   Triple Negative Breast Cancer;   Advanced Melanoma;   B-cell Malignancy, Low-grade
Interventions: Drug: E7449 alone;   Drug: E7449 plus TMZ;   Drug: E7449 plus carboplatin and paclitaxel
3 Recruiting Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer
Conditions: brca1 Mutation Carrier;   brca2 Mutation Carrier;   Breast Cancer;   Ovarian Cancer
Interventions: Drug: rucaparib (CO-338; formally AG-014699 or PF-01367338);   Genetic: protein expression analysis;   Genetic: western blotting;   Other: immunohistochemistry staining method;   Other: liquid chromatography;   Other: mass spectrometry;   Other: pharmacological study
4 Recruiting Olaparib in Combination With Carboplatin for Refractory or Recurrent Women's Cancers
Conditions: Mixed Muellerian Cancer;   Cervical Cancer;   Ovarian Cancer;   Breast Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer;   Endometrial Cancer;   Carcinosarcoma
Interventions: Drug: Carboplatin;   Drug: Olaparib;   Drug: Treatment Effect
5 Recruiting Phase I of BKM120/Olaparib for Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Conditions: Ovarian Cancer;   Breast Cancer
Intervention: Drug: BKM120 and Olaparib
6 Recruiting Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
Conditions: Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: veliparib;   Drug: topotecan hydrochloride;   Other: pharmacogenomic studies;   Other: pharmacological study;   Other: laboratory biomarker analysis
7 Recruiting A Study of Oral Rucaparib in Patients With gBRCA Mutation Breast or Ovarian Cancer, or Other Solid Tumor
Conditions: Metastatic Solid Tumor;   Breast Cancer;   Ovarian Cancer
Intervention: Drug: Rucaparib
8 Recruiting Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation
Condition: Recurrent, Epithelial Ovarian Cancer
Intervention: Drug: Veliparib
9 Not yet recruiting Olaparib Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Conditions: Newly Diagnosed;   Advanced Ovarian Cancer;   FIGO Stage II-IV;   BRCA Mutation;   Complete Response;   Partial Response;   First Line Platinum Chemotherapy
Intervention: Drug: Olaparib 300mg tablets
10 Recruiting Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Conditions: Advanced or Recurrent Solid Tumors;   Breast Neoplasms;   Ovarian Cancer, Epithelial;   Ewing Sarcoma;   Small Cell Lung Carcinoma;   Prostate Cancer;   Pancreas Cancer
Intervention: Drug: BMN 673
11 Recruiting Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Hereditary Breast/Ovarian Cancer - BRCA1;   Hereditary Breast/Ovarian Cancer - BRCA2;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Other: immunohistochemistry staining method;   Genetic: gene expression analysis;   Drug: veliparib;   Drug: cisplatin;   Drug: vinorelbine tartrate;   Other: pharmacological study;   Other: laboratory biomarker analysis
12 Recruiting Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Estrogen Receptor-negative Breast Cancer;   Fallopian Tube Cancer;   HER2-negative Breast Cancer;   Hereditary Breast/Ovarian Cancer (BRCA1, BRCA2);   Male Breast Cancer;   Primary Peritoneal Cavity Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Pancreatic Cancer;   Recurrent Prostate Cancer;   Triple-negative Breast Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: veliparib;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study
13 Recruiting Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Conditions: Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Drug: veliparib;   Drug: floxuridine;   Other: pharmacological study;   Other: pharmacogenomic studies;   Other: laboratory biomarker analysis
14 Recruiting Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Brenner Tumor;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Biological: bevacizumab;   Drug: veliparib;   Other: laboratory biomarker analysis
15 Recruiting Cediranib and Olaparib in Combination for Recurrent Ovarian or Triple-Negative Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Papillary Serous Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Triple-negative Breast Cancer
Interventions: Drug: olaparib;   Drug: cediranib maleate;   Other: laboratory biomarker analysis
To Top

† Indicates status has not been verified in more than two years